6533b85dfe1ef96bd12bf159
RESEARCH PRODUCT
Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness
Manuel Díaz-llopisMaria D Pinazo-duransubject
Treated groupgenetic structuresbusiness.industryCycloplegiaGeneral Medicine03 medical and health sciencesAtropine0302 clinical medicineAnesthesia030221 ophthalmology & optometrymedicinemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugdescription
Abstract Objective To confirm the clinical security and effectiveness of the daily application of 0.01% superdiluted atropine eyedrops in the progression of myopia in children. Material and methods A total of 200 children 9–12 years of age were randomized into a treated group and a control without treatment. Refraction under cycloplegia was performed. Results Myopia progression of the treated group was −0.14 ± 0.35 versus −0.65 ± 0.54 in the control group without treatment. Only 2% of patients were forced to stop treatment due to side effects. Conclusion Atropine superdiluted atropine 0.01% eyedrops is effective and well tolerated, and reduced myopia progression by 25%.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-04-01 | Archivos de la Sociedad Española de Oftalmología (English Edition) |